drugset / Trial / NCT01124188

ADAPT: Addressing Depression and Pain Together

NCT01124188 ↗

Phase 4 Completed 263 enrolled University of Pittsburgh
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary question addressed by this study is: Using a stepped care approach in primary care, what is the value of the combination of an antidepressant medication (Venlafaxine) and psychotherapy for seniors living with depression and chronic lower back pain when treatment with a low-dose of venlafaxine and supportive management (SM) has led to only a partial or non-response?

Timeline

Start
2010-05
Primary completion
2016-02
Completion
2016-02

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Study Intervention Arm vs Active Control; Hazard Ratio (HR) 1.07 (95% CI 0.63 to 1.80) NCT01124188 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Venlafaxine Small molecule 187.5 mg —
Subject Venlafaxine Small molecule 300 mg —

Indications